Diseases

Developer and manufacturer of rapid non-invasive diagnostic tests for gastrointestinal diseases, TECHLAB sought U.S FDA's clearance for the CAMPYLOBACTER QUIK CHEK and the CAMPYLOBACTER…
Read More...

The company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, BioAtla asserted that the U.S FDA has cleared Investigational New Drug application…
Read More...

Perrigo Company sought U.S FDA's approval for the launch of generic version of Epiduo (adapalene and benzoyl peroxide) Gel, 0.1%/2.5%. Perrigo Executive Vice President and President…
Read More...

U.S Food and Drug Administration approved Perrigo Company's generic version of Estrace Cream anticipated to be launched in the second quarter of the year. Constituents of the cream are…
Read More...

Late-stage clinical biopharmaceutical company, Liquidia Technologies focused on enhancing the performance of medicine by precisely engineering drug particles, today announced positive…
Read More...

Pixium Vision, Company committed to curating bionic vision systems ensuring revival of lost sight to patients, asserted the world’s first successful human implantation and activation of…
Read More...

COMPASS Trial results suggest affirmative Penumbra;s approach to effective thrombectomy approach for acute ischemic stroke as part of the ADAPT (A DirectAspiration, First Pass …
Read More...

European Medicines Agency asserted that Alnylam Pharmaceutical's application for Marketing Authorisation has been accepted for review of for patisiran, an investigational RNAi…
Read More...

Chinese Center for Drug Evaluation has sanctioned an expansion of  expansion of the indications for Aggrastat for pharmaceutical company focused on commercializing patent-protected…
Read More...

Swedish Orphan Biovitrum AB confirmed FDA's acceptance of the investigational new drug application for the drug candidate SOBI003 along with granting Fast track status to it. SOBI003 is…
Read More...

Evofem Biosciences committed to the development and commercialization of women's healthcare products asserted the enrollment of its first patient in  Phase 2b/3 clinical trial…
Read More...

ProMIS Neurosciences committed to the discovery and development of precision treatments for neurodegenerative diseases, announced further results of its previously announced and ongoing…
Read More...

Biomarck Pharmaceuticals affirmed initiation of Phase 2 Clinical study in advanced NSCLC.  The study is meant to compare  standard of Care Therapy alone to SOC plus BIO-11006. BIO-11006…
Read More...

U.S FDA grants clearance for QIAGEN's ipsogen JAK2 RGQ PCR Kit for ascertaining myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the…
Read More...

Puma Biotechnology asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has conveyed a negative trend vote after discussions…
Read More...

Cerus Corporation asserted successful achievement of primary efficacy and safety endpoints in the Company's Phase 3 transfusion study of Chronic anaemia assessing INTERCEPT-treated Red…
Read More...

Seattle Genetics confirmed that its collaborator, Takeda Pharmaceutical Company Limited has asserted the fact that European Commission has extended the current conditional marketing…
Read More...

In order to offer a robust, and economically viable solution for anatomical pathology, Enzo Biochem asserted the authentication of a cervical Cancer biomarker detection test offering a…
Read More...

Baxter asserted the approval of U.S. Food and Drug Administration for Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Baxter's premixed medications are manufactured…
Read More...

U.S FDA has granted 510 (k) clearance to Bio-Rad Laboratories for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents…
Read More...